ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

Vibeke Backer and Prof. Sietze Reitsma contribute their insights. Crucially, the symposium will also focus on future directions, including emerging therapies, personalized medicine approaches, and innovative strategies aimed at achieving better disease control and improved patient outcomes in CRSwNP.

DMSc, MD

Vibeke Backer +1 more

23 - 24Jun2025

Begins in

6days

19hours

Agenda

Welcome & Introductions

Vibeke Backer

Type 2 Inflammation: Links With Severe/Uncontrolled CRSwNP

Vibeke Backer

Treatable Traits in CRSwNP

Sietze Reitsma

Regulatory-Approved Biologics for CRSwNP: A Clinical Overview and Update

Sietze Reitsma

Disease Control in CRSwNP

Vibeke Backer

Audience Q&A

All Faculty

Speakers

Pulmonology

DMSc, MD

Vibeke Backer

Chief Respiratory Physician, Department of ENT and Centre for Physical Activity Research | Rigshospitalet, Copenhagen, Denmark

Rhinology

MD, PhD

Sietze Reitsma

ENT and Rhinologist at the University Medical Centres in Amsterdam | Professor at the Department of Otorhinolaryngology and Head and Neck Surgery | University of Amsterdam

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region